• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

p53 gene therapy for esophageal cancer

Research Project

Project/Area Number 09671282
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionCHIBA UNIVERSITY SCHOOL OF MEDICINE

Principal Investigator

OCHIAI Takenori  Chiba University School of Medicine, Surgery, Professor, 医学部, 教授 (80114255)

Co-Investigator(Kenkyū-buntansha) MATSUBARA Hisahiro  Chiba University School of Medicine, Surgery, Assistsnt, 医学部附属病院, 助手 (20282486)
SHIMADA Hideaki  Chiba University School of Medicine, Surgery, Assistsnt, 医学部附属病院, 助手 (20292691)
磯野 可一  千葉大学, 医学部, 助手 (70009489)
中島 一彰  千葉大学, 医学部, 助手 (20261919)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥2,500,000 (Direct Cost: ¥2,500,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1997: ¥1,400,000 (Direct Cost: ¥1,400,000)
Keywordsp53 / gene-therapy / esophageal cancer / p53遺伝子 / p16遺伝子 / p53アデノウイルスベクター
Research Abstract

Background ; Despite improvements in perioperative adjuvant therapy, survival ratio is still very low among many patients with advanced esophageal cancer. Alteration of the p53 gene function is a major factor in the development of esophageal cancer. We examined the efficacy of an adenovirus- mediated wild-type p53 gene transfer on the proliferation of human esophageal squamous cell carcinoma cells with and without p53 gene mutation in in vitro as well as in vivo to test the ability of clinical application. Methods ; Seven human esophageal cancer cell lines (EGGI-10, T.Tn, TE-1, TE-10, TE-1 1, TE-13) with p53 alteration and one cell lines (TE-2) without p53 alteration were used. p16 genetic alteration was evident in TE-10, TE-1 1, TE-13, EGGI-10. The transduction efficiency, p53 expression, and growth suppression were assessed in in vitro in these cell lines by infecting the recombinant p53 adenoviral vector or LacZ vector. The tumor growth suppression in vivo was assessed in nude mice bearing T.Tn tumors. Results ; The trasnduciton efficiency was 60% with 100 MOI infection. In vitro growth assays revealed significant growth suppression following 30 or more MOI of p53 adenoviral vector, In vivo studies in nude mice showed that tumor volume were reduced in mice that received intratumoral injection of p53 adenoviral vector. Conclusion ; These data suggest that p53 adenoviral vector may be a potential therapeutic agent for locally advanced esophageal cancer.

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (10 results)

All Other

All Publications (10 results)

  • [Publications] Hideaki Shimada et al: "Detection of Saram P53 antibodies in patients with esophageal squamous cell carcinoma : Correlation with clinica Pathological features and tumor markor" Oncology Reports. 5. 871-874 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Hideaki Shimada et al: "Dotection of Seram P53 antibodies in mucosal esophageal concer and negative conversion after treatment" Am J Gastroenterology. 93. 1388-1389 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Hisahiro Matsubara et al: "Antitumor response of genetically engeneered IL-2 expression to human esophageal carcinoma cells in mature Tcell-defective condition" Int J Oncol. 13(6). 1217-1222 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shimda H、 Matubara H、 Ochiai T: "p53 gene therapy for esophageal cancer" SHOUKAKI-KA. 25 (1). 38-42 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H.Shimada, T Ochiai et al: "Detection of serum p53 antibodies in patients with esophageal squamouse cell carcinoma : Correlation with clinicopathological features and tumor markers." Oncology Reports. 5. 871-874 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H Shimada, T,Ochiai et al: "Detection of serum p53 antibodoes in mucosal esophageal cancer and negative conversion after treatment" Am J Gastroenterology. 93. 1388-1389 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] H Shimada, T Ochiai, et al: "Preclinical study of p53 adenoviral gene therapy for esophageal carcinoma." 4th annual meeting of the Japan Society of Gene Therapy (Tokyo) 7/4-7/5. (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Hideaki Shimada et al: "Detection of Serum p53 antibodies in patients with esaphageal squamous cell Carcinoma:Correlation with clinico pathological features and tumor markone" Oncology Reports. 5. 871-874 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Hideaki Shimada et al: "Detection of Serum p53 antibodies in mucosal esophageal cancer and negatire conversionafter treatment" Am J Ctastroenterology. 93. 1388-1389 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Hisahiro Matsubara et al: "Antitumor response of genetically enyeneered IL-2 expression to human esophageal carcinoma cells in mature Tcell-defective condition" Int J Oncol. 13(6). 1217-1222 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi